Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Abroad (travel likely)RecruitingPHASE3
Conditions
Renal Cell Carcinoma · Neoadjuvant
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Contact: Study coordinator (Sujun Han, Dr)Peking University First Hospital, Beijing, China
Contact: Study coordinator (Zhisong He, Dr)Sun Yat-sen University Cancer Center, Guangzhou, China
Contact: Study coordinator (Zhiling Zhang, Dr)Anhui Provincial Hospital, Hefei, China
Contact: Study coordinator (JUn Xiao, Dr)Fudan University Cancer Hospital, Shanghai, China
Contact: Study coordinator (Hailiang Zhang, Dr)West China Hospital, Sichuan, China
Contact: Study coordinator (Hao Zeng, Dr)Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Contact: Study coordinator (Yao Xin, Dr)The First Affiliated Hospital of Zhengzhou Hospital, Zhengzhou, China
Contact: Study coordinator (Xuepei Zhang, Dr)
Study leads
Fangjian Zhou, Professor
Principal Investigator
Director of Dept. of Urology, Sun Yat-sen University Cancer Center